Efficacy of Autologous Bone Marrow Concentrate for Knee Osteoarthritis with and without Adipose Graft:
A recent study published in BioMed Research International in September 2014 examined the effects of Bone Marrow Concentrate (BMC) with and without adipose grafting on knee Osteoarthritis (OA). The study collected data on 840 intra-articular BMC knee injections (616 BMC only and 224 BMC + adipose graft) via a prospective treatment registry. The registry included outcome and complications questionnaires, completed at 1,3,6 and 12 months post procedure by patients from 17 different outpatient clinics, the majority of which came from Dr. Christopher Centeno’s clinic. In addition, investigators specifically analyzed pre- and post-treatment outcomes using the lower extremity functional scale (LEFS), numerical pain scale (NPS) and a subjective percentage improvement rating. Frequency and type of adverse events were also analyzed.
The results indicated statistically significant improvements in pre/post LEFS and NPS scores within each group. However, there was no differences seen between the BMC and the BMC + adipose graft groups except for subjective percentage improvement scale, 46.8% and 39.3%, respectively. A correlation was noted between lower severity arthritis and better improvement on the subjective percentage improvement scale. In addition, females and those with higher BMIs were more likely to report improvements on the LEFS scale. Pain and swelling was the most commonly reported adverse event, with no significant difference between the two groups. Compared to previous studies regarding adverse events in total knee arthroplasty (TKA), the overall safety of BMC injection with and without adipose graft injection appears to be substantially better than TKA.
The results from the registry data analysis suggest a positive benefit from intraarticular injection of BMC for knee OA. Although no obvious benefit from adipose grafting was noted, both groups revealed statistically significant improvements in pain and lower extremity function with minimal adverse outcomes. Furthermore, the reported complications for both groups were far less than those reported for knee arthroplasty in the orthopedic literature. The study adds to a growing volume of literature suggesting that BMC injections may potentially be a safe and efficacious alternative to earlier surgical intervention for knee OA. However, continued research collaboration and randomized controlled trials are still needed to substantiate the results and further investigate the effectiveness of BMC in Osteoarthritis treatment.
For all of the latest research and protocols in regenerative medicine, including bone marrow concentrate and adipose, be sure to attend the 6th Annual TOBI: The Orthobiologic Institute PRP & Regenerative Medicine Symposium with Cadaver Lab June 12-14, 2015 in Las Vegas, www.prpseminar.com,
Author of blog: Kristin Garlanger, DO